The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10588 malaria professionals are enjoying the free benefits of MalariaWorld today

chloroquine-resistant

An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in...

September 16, 2020 - 12:48 -- Open Access
Author(s): 
Jeffrey Livezey, Patrick Twomey, Paige Waterman, et al.
Reference: 
Malaria Journal 2020 19:336, 16 September 2020

Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro.

Global assessment of genetic paradigms of Pvmdr1 mutations in chloroquine-resistant Plasmodium vivax isolates

March 3, 2020 - 12:31 -- Open Access
Author(s): 
Spotin A, Mahami-Oskouei M, Ahmadpour E, Parsaei M, Rostami A, Emami S, Gholipour S, Farmani M
Reference: 
Transactions of The Royal Society of Tropical Medicine and Hygiene, traa002

Chloroquine (CQ) is generally prescribed as the front-line antimalarial drug of choice to treat Plasmodium vivax infections; however, some clinical CQ-resistant P. vivax isolates have been indigenously reported around the world during the last decade.

Subscribe to RSS - chloroquine-resistant